By signing an executive order, President Donald Trump has shifted marijuana from a Schedule I to a Schedule III controlled substance, opening the door for medical and research uses nationwide. 

A new report from the New York Times reveals a system of de facto quid pro quo where wealthy patients from oil-rich nations are sometimes moved to the top of organ transplant lists.

The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy." 

The label is the most serious warning the agency can place on pharmaceuticals, denoting substances that carry serious health risks that must be weighed against benefits. CNN was the first to report the news, citing two sources familiar with the matter. 

Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.

The nylon loop on some devices can fail to release while removing polyps. Because of the severe risk to patient health, the FDA has designated this recall a Class I.

Authorities allege the pharmacy chain gave patients more insulin than prescribed and then billed Medicare and Medicaid for the full amounts. This allegedly occurred for more than a decade. 

The infusion system modules can malfunction if dropped or jarred without the user noticing. Manufacturer Becton Dickinson is asking owners to inspect the devices to ensure they are safe to use.